Placeholder

Coming into focus

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1826. Categories: , .

Product Description

    For years, the pharmaceutical powerhouses have either been U.S. or European companies, and all have extensive operations in the U.S. Of the top 10 pharmaceutical companies, six are U.S.-based companies, the remaining four have their headquarters either in the United Kingdom or continental Europe, according to data from IMS Health. There are no Japanese companies in the top 10, despite that market’s status as the second largest in the world. However, several Japanese companies are making inroads in the U.S. market, relying less on alliances and more on building their own marketing infrastructure and R&D operations.
    According to Mikihiko Obayashi, Ph.D., who leads the Japan International Desk — a division of Quintiles Transnational Corp. that offers consulting services to Japanese pharmaceutical companies wishing to enter or expand in overseas markets — there are currently between 40 and 50 Japanese companies conducting clinical trials in the U.S.
    “Of those, about 10 plan to register products on their own and the others will license their compound to a local company for Phase III trials…

Sidebar:
Western Eyes on Eastern Markets
Fujisawa: on its way to $1 billion


Experts on this topic

Peter Labadie. President, Williams-Labadie, Chicago; Williams-Labadie is a full-service healthcare advertising agency
Kurt Lewis. Senior VP, Marketing and Sales, Fujisawa Healthcare Inc., Deerfield, Ill., a subsidiary of Fujisawa Pharmaceutical Co. Ltd of Osaka, Japan; Fujisawa Pharmaceutical is a leading pharmaceutical manufacturer with operations in North America, Japan, Europe, and Asia
Steve Mader. Senior VP, Marketing and Sales, Yamanouchi America Inc., Paramus, N.J., a subsidiary of Yamanouchi Pharmaceutical Co. Ltd.; Yamanouchi is the third-largest pharmaceutical company in Japan
Cameron Munro. Senior VP, Account Group Supervisor, Lyons Lavey Nickel Swift Inc., New?York; Lyons Lavey Nickel Swift is a full-service healthcare advertising agency
Mikihiko Obayashi, Ph.D. President, Japan International Desk, Princeton, N.J.; JID is a division of Quintiles Transnational Corp, a leading provider of information, technology, and services to the healthcare industry
John Schroeter. President of The Synapse Group, Burlington, Ontario; The Synapse Group is a full-service advertising agency
Bill Sheldon. President and chief operating officer, Eisai Inc., Teaneck, N.J.; Eisai Inc. is the U.S. pharmaceutical operations of Eisai Co. Ltd. of Japan, which discovers, develops, and markets products in more than 30 countries

FEEDBACK